Walgreens Owner Nears $9 Billion Deal to Sell Boots Chain
Sycamore Partners, the private-equity owner of Walgreens, is nearing a deal to sell British pharmacy and health-and-beauty retailer Boots for approximately $9 billion, including debt, according to a Wall Street Journal report published September 30, 2026. The prospective buyer is the Canadian arm of the Weston family, which has major interests in grocery and pharmacy businesses.
The transaction has not yet been finalized. Reuters reported that the deal could be completed in the coming weeks if negotiations continue without breaking down. Sycamore and Boots have not publicly confirmed the reported transaction.
The potential sale is significant because it would mark another major step in Sycamore's restructuring of the former Walgreens Boots Alliance business and could give the private-equity firm greater flexibility to focus on Walgreens' U.S. operations.
Sycamore Moves to Sell Boots After Walgreens Takeover
Sycamore completed its acquisition of Walgreens Boots Alliance in August 2025. The transaction was valued at up to approximately $23.7 billion, including potential additional value tied to divested assets. Walgreens subsequently became a private standalone company.
Following the takeover, Sycamore separated the former Walgreens Boots Alliance operations into five standalone businesses. Boots was among the assets positioned separately, making a future sale possible.
The strategy effectively separates the British retail and healthcare business from Walgreens' U.S. pharmacy operations. Reuters said the move is part of Sycamore's broader plan following its acquisition of Walgreens, while the WSJ reported that the private-equity firm is seeking to concentrate on the U.S. business, which has roughly 8,000 stores.
Who Could Buy Boots?
The reported buyer is the Canadian arm of the Weston family, a prominent business family with interests in food and healthcare.
The family has connections to Canadian grocery and pharmacy businesses through Wittington Investments, including Loblaw and Shoppers Drug Mart. Its broader business interests also include Associated British Foods in the U.K.
For the Weston family, acquiring Boots would provide control of a major British pharmacy and beauty retailer while expanding its exposure to healthcare and consumer retail.
The transaction would also represent a return to a more substantial position in British retail for the family after the sale of Selfridges in 2022, although it retains other U.K. interests.
Boots Has Been Showing Signs of Recovery
The reported sale comes at a time when Boots' underlying business has shown improvement.
The retailer generated approximately £7.5 billion in revenue, up 3.2%, while pre-tax profit increased 25% to £337 million in its latest reported financial period. The Financial Times said growth was supported by beauty products and demand related to weight-loss treatments.
Boots also operates more than 1,800 stores across Britain and remains an important provider of pharmacy services, including services connected with the U.K.'s National Health Service.
That combination of a large physical store network, pharmacy operations and a substantial beauty business could make Boots strategically attractive to a buyer seeking a long-term consumer-health platform.
Sale vs. Potential Boots IPO
The potential acquisition also changes the outlook for Boots' previously discussed plans to access public markets.
Earlier in 2026, Boots had been working on a strategy that included the possibility of a London listing as soon as 2027. A sale to the Weston family would provide Sycamore with an alternative exit route instead of waiting for an IPO.
This is an important distinction for investors watching the U.K. market. A Boots IPO could have created a new publicly traded consumer-health and pharmacy company in London. A private sale, by contrast, would keep the business under private ownership and transfer the potential future upside to the new owner.
What the Deal Means for Sycamore and Walgreens
For Sycamore, the reported $9 billion Boots transaction could provide a significant monetization event relatively soon after acquiring Walgreens.
Private-equity firms typically look for opportunities to improve businesses, separate assets and eventually sell investments or individual divisions. Selling Boots would fit that approach by turning a non-U.S. operation into cash while allowing Sycamore to concentrate more directly on Walgreens' American business.
However, the reported price should not be interpreted as a direct profit figure for Sycamore. The approximately $9 billion valuation includes debt, and the economics of the transaction will depend on the final purchase price, debt arrangements, transaction costs and the capital invested in Boots.
For Walgreens itself, the separation removes Boots from the company's operating structure and leaves the U.S. pharmacy business as the central focus of its turnaround strategy. Walgreens became private under Sycamore in 2025, so there is no longer a publicly traded WBA stock through which ordinary investors can directly track the company.
What Investors Should Watch Next
The immediate catalyst is whether Sycamore and the Weston family's Canadian business reach a definitive agreement.
Investors and industry watchers should focus on several details if the deal is announced:
The final purchase price and whether the reported $9 billion includes all assumed debt.
The ownership structure and financing of the acquisition.
Whether Boots' potential London IPO plans are formally abandoned.
How the new owner plans to invest in stores, pharmacy services and beauty operations.
Whether Sycamore uses proceeds from the transaction to accelerate its Walgreens turnaround.
Any regulatory or competition-related requirements attached to the transaction.
The broader significance extends beyond Boots. The deal illustrates how large retail and pharmacy groups are being reshaped through private-equity ownership, asset sales and consolidation. Healthcare retail businesses are increasingly combining pharmacy services with beauty, wellness and consumer products, making the strategic value of established store networks more complicated than simply measuring prescription volumes.
Bottom Line
Sycamore Partners is reportedly close to selling Boots to the Canadian arm of the Weston family for around $9 billion including debt, but the transaction remains subject to final negotiations.
For Sycamore, the sale would represent a major step in separating Walgreens' international assets from its U.S. pharmacy operations. For the Weston family, it could create a sizable new position in British healthcare and retail. The key development now is whether the reported agreement becomes a definitive transaction and what the final financial terms reveal about Boots' valuation.
Follow the blog for more updates on global companies, business deals, financial markets and major corporate developments.
This article is for informational and educational purposes only and should not be considered investment advice.